Compare Divis Laboratories with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs GSK PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES GSK PHARMA DIVIS LABORATORIES/
GSK PHARMA
 
P/E (TTM) x 59.8 -82.7 - View Chart
P/BV x 13.8 12.3 111.9% View Chart
Dividend Yield % 0.4 1.3 34.5%  

Financials

 DIVIS LABORATORIES   GSK PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
GSK PHARMA
Mar-19
DIVIS LABORATORIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,6393,595 45.6%   
Low Rs1,1151,253 89.0%   
Sales per share (Unadj.) Rs186.3184.7 100.9%  
Earnings per share (Unadj.) Rs51.026.3 193.8%  
Cash flow per share (Unadj.) Rs57.329.2 196.6%  
Dividends per share (Unadj.) Rs16.0020.00 80.0%  
Dividend yield (eoy) %1.20.8 140.8%  
Book value per share (Unadj.) Rs261.8126.3 207.2%  
Shares outstanding (eoy) m265.47169.40 156.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.413.1 56.3%   
Avg P/E ratio x27.092.2 29.3%  
P/CF ratio (eoy) x24.083.1 28.9%  
Price / Book Value ratio x5.319.2 27.4%  
Dividend payout %31.476.1 41.3%   
Avg Mkt Cap Rs m365,592410,626 89.0%   
No. of employees `00011.85.0 238.9%   
Total wages/salary Rs m5,4235,372 100.9%   
Avg. sales/employee Rs Th4,175.16,306.7 66.2%   
Avg. wages/employee Rs Th457.71,083.1 42.3%   
Avg. net profit/employee Rs Th1,141.8898.0 127.2%   
INCOME DATA
Net Sales Rs m49,46331,281 158.1%  
Other income Rs m1,5561,023 152.1%   
Total revenues Rs m51,01932,304 157.9%   
Gross profit Rs m18,7186,009 311.5%  
Depreciation Rs m1,689486 347.5%   
Interest Rs m356 583.3%   
Profit before tax Rs m18,5516,540 283.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m5,0232,373 211.7%   
Profit after tax Rs m13,5274,454 303.7%  
Gross profit margin %37.819.2 197.0%  
Effective tax rate %27.136.3 74.6%   
Net profit margin %27.314.2 192.1%  
BALANCE SHEET DATA
Current assets Rs m46,50120,061 231.8%   
Current liabilities Rs m8,46814,543 58.2%   
Net working cap to sales %76.917.6 435.9%  
Current ratio x5.51.4 398.1%  
Inventory Days Days13157 230.4%  
Debtors Days Days8614 610.6%  
Net fixed assets Rs m25,79714,343 179.9%   
Share capital Rs m5311,694 31.3%   
"Free" reserves Rs m68,96219,704 350.0%   
Net worth Rs m69,49321,398 324.8%   
Long term debt Rs m02 0.0%   
Total assets Rs m80,38339,113 205.5%  
Interest coverage x531.01,091.0 48.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.8 76.9%   
Return on assets %16.911.4 148.0%  
Return on equity %19.520.8 93.5%  
Return on capital %26.731.9 83.8%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,238534 7,722.4%   
Fx outflow Rs m12,4057,091 174.9%   
Net fx Rs m28,833-6,557 -439.7%   
CASH FLOW
From Operations Rs m9,5433,994 238.9%  
From Investments Rs m-6,854-1,433 478.2%  
From Financial Activity Rs m-2,459-3,584 68.6%  
Net Cashflow Rs m230-1,023 -22.4%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 11.8 10.2 115.7%  
FIIs % 19.0 23.8 79.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 15.4 111.7%  
Shareholders   31,796 102,036 31.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   NATCO PHARMA  FRESENIUS KABI ONCO.  FDC.  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 110 Points Lower; Smallcap & Midcap Stocks Outperform(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower, ahead of Q2 GDP data.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks(Profit Hunter)

Nov 25, 2020

India's drones directorate signals the next big defence tech multibaggers.

Stocks that Could Shine More than Gold After Diwali(Profit Hunter)

Nov 17, 2020

If the markets become volatile over the next few months, do this.

It's Time to Book Profits(Fast Profits Daily)

Nov 27, 2020

In my first video on Equitymaster, I want to introduce you my proprietary greed and fear index. It's telling us to book some profits in the market.

How the New Margins Will Impact You(Fast Profits Daily)

Nov 25, 2020

The new rules on margins will come into effect from 1st December. Are you ready?

An Eraser and Some Pencils(The Honest Truth)

Nov 17, 2020

Ajit Dayal on the road ahead for the world after covid.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Nov 27, 2020 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS